IVACAFTOR and HOSPITALISATION

1,286 reports of this reaction

14.0% of all IVACAFTOR reports

#1 most reported adverse reaction

Overview

HOSPITALISATION is the #1 most commonly reported adverse reaction for IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 1,286 FDA adverse event reports linking IVACAFTOR to HOSPITALISATION. This represents approximately 14.0% of all 9,200 adverse event reports for this drug.

Patients taking IVACAFTOR who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

HOSPITALISATION1,286 of 9,200 reports

HOSPITALISATION is a frequently reported adverse event for IVACAFTOR, accounting for a significant proportion of all reports.

Other Side Effects of IVACAFTOR

In addition to hospitalisation, the following adverse reactions have been reported for IVACAFTOR:

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS — 601 reports
PNEUMONIA — 262 reports
INFECTION — 249 reports
MALAISE — 247 reports
LOWER RESPIRATORY TRACT INFECTION — 242 reports
DEATH — 224 reports
COUGH — 219 reports
CYSTIC FIBROSIS — 211 reports
HEADACHE — 194 reports
NASOPHARYNGITIS — 168 reports

Other Drugs Associated with HOSPITALISATION

The following drugs have also been linked to hospitalisation in FDA adverse event reports:

ABIRATERONE ACETATE ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, DIMETHICONE AMIKACIN APALUTAMIDE CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES CINACALCET HYDROCHLORIDE CLOZAPINE DARBEPOETIN ALFA DASATINIB DORNASE ALFA ECULIZUMAB ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR EPOPROSTENOL SODIUM ESKETAMINE HYDROCHLORIDE FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 LEVOCARNITINE LUMACAFTOR AND IVACAFTOR MACITENTAN MEPOLIZUMAB

Frequently Asked Questions

Does IVACAFTOR cause HOSPITALISATION?

HOSPITALISATION has been reported as an adverse event in 1,286 FDA reports for IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is HOSPITALISATION with IVACAFTOR?

HOSPITALISATION accounts for approximately 14.0% of all adverse event reports for IVACAFTOR, making it one of the most commonly reported side effect.

What should I do if I experience HOSPITALISATION while taking IVACAFTOR?

If you experience hospitalisation while taking IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

IVACAFTOR Full Profile All Drugs Causing HOSPITALISATION Vertex Pharmaceuticals Incorporated Drugs

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.